COST-EFFECTIVENESS OF EMPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT INCREASED CARDIOVASCULAR RISK IN GREECE

Abstract

Abstract is not available.

    Similar works